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Background: Supplementation with a phosphatidylserine and phosphatidylserine/ phosphatidic acid complex
(PAS) has been observed to normalize stress induced dysregulations of the hypothalamus-pituitary-adrenal axis
(HPAA). Prolonged stress first induces a hyper-activation of the HPAA, which then can be followed by a state of
hypo-activation.
The aim of this study was to examine effects of an oral supplementation with 400 mg PS & 400 mg PA (PAS 400)
per day on the endocrine stress response (ACTH, saliva and serum cortisol) to a psychosocial stressor. A special
focus was to analyze subgroups of low versus high chronically stressed subjects as well as to test efficacy of
200 mg PS & 200 mg PA (PAS 200).
Methods: 75 healthy male volunteers were enrolled for this double-blind, placebo-controlled study, stratified by
chronic stress level, and randomly allocated to one of three study arms (placebo, PAS 200 and PAS 400 per day,
respectively). Study supplementation was administered for 42 days for each participant. Chronic stress was
measured with the Trier Inventory for Chronic Stress (TICS), and subgroups of high and low chronic stress were
differentiated by median values as provided by the TICS authors. A six week period of supplementation was
followed by an acute stress test (Trier Social Stress Test - TSST).
Results: Chronic stress levels and other baseline measures did not differ between treatment groups (all p > 0.05).
Acute stress was successfully induced by the TSST and resulted in a hyper-responsivity of the HPAA in chronically
stressed subjects. Compared to placebo, a supplementation with a daily dose of PAS 400 was effective in normalizing
the ACTH (p = 0.010), salivary (p = 0.043) and serum cortisol responses (p = 0.035) to the TSST in chronically high but
not in low stressed subjects (all p > 0.05). Compared to placebo, supplementation with PAS 200 did not result in any
significant differences in these variables (all p > 0.05). There were no significant effects of supplementation with PAS on
heart rate, pulse transit time, or psychological stress response (all p > 0.05).
Conclusion: In chronically stressed subjects, a supplementation with PAS 400 (MemreePlus™) can normalize the
hyper-responsivity of the HPAA to an acute stressor.
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Stress is an individual response to external and internal
challenges ranging from behavioral to molecular adap-
tions, affecting the stress response network in the central
nervous system and its crosstalk with peripheral organs
via the endocrine and the autonomic nervous systems
[1]. The hypothalamic-pituitary-adrenal axis (HPAA) plays
a central role in such adaptation processes of the organism
[2]. In response to acute stressors, the hypothalamus se-
cretes corticotropin–releasing factor, which triggers the
release of adrenocorticotropic hormone (ACTH) from the
pituitary gland. ACTH then promotes the release of corti-
sol from the adrenal cortex. Cortisol affects numerous
physiological functions, such as carbohydrate, lipid and
protein metabolism, the immune system, and enhances
the energy supply of the central nervous system. Chronic
psychological stress has been shown to induce dysregula-
tions of the HPAA, which are associated with impaired
psychological and somatic well-being. Under such condi-
tions, a biphasic response of the HPAA has been observed:
prolonged psychological stress may first induce a hyper-
activation of the HPAA, which may then be followed by a
state of hypo-activation [3,4]. While a hyper-activation of
the HPAA has been shown to be associated with stress re-
lated disorders such as melancholic depression, anxiety
disorders, and metabolic syndrome, a hypo-activation is
rather linked to fatigue, pain, irritability and associated
disorders such as fibromyalgia, arthritis, and chronic fa-
tigue syndrome [5-7]. Thus, a hyper-activation of the
HPAA seems to be associated with a hyper-reactivity to
acute stress, while a reduced synthesis of cortisol may
mainly account for a hypoactive state [6,8-12].
Recent research showed that the intake of certain
nutraceuticals reversed or normalized such dysregulations
and improved stress symptomatology. For example, the
intake of fertilized egg powder for the duration of four
weeks normalized the psychological and physiological
stress response in chronically stressed but otherwise
healthy males [13]. Moreover, studies on different sub-
stances enriched with phospholipids have shown benefi-
cial effects in chronically stressed subjects. It has been
suggested that milk phospholipids may increase cortisol
availability in subjects with high chronic stress [13-15].
Phosphatidic acid (PA) is one of the most important
glycerophospholipids found in bio-membranes. PA has
different roles in the cell: it is a precursor for other lipids
such as phosphatidylserine (PS) or phosphatidylcholine
via the conversion of PA to diacylglycerol [16]. More-
over, PA influences membrane curvature [17,18] and
acts as signaling lipid [19,20]. Animal research suggests
that PA may prevent or restore gastrointestinal disorders
[21,22] and may increase skeletal muscle mass [23]. PS
plays a key role in neuronal cell structure and functioning
and may improve memory, learning, mood and stressmanagement [24-29]. PS has been shown to decrease
ACTH and cortisol responses to acute physical and men-
tal stress [30-35]. Additionally, the intake of PS has been
associated with an improvement of psychiatric disorders,
such as bipolar and major depressive disorders reviewed
in [26,36], as well as with the prevention of inflammatory
neurodegenerative events [37].
Moreover, in combination with PS, PA has been shown
to reduce cortisol levels and enhance well-being under
acute social stress. In a previous study, we could show
that the administration of PAS 400 per day over a period
of 21 days resulted in both a significant decrease of the
ACTH- and cortisol-response, and, in addition, a reduction
of anxiety to the TSST [27]. The exact mechanisms on
how PA and PS contribute to an adaptation of the stress
response network are still unknown. Several stress-related
disorders such as depression and mood disorders have
been associated with fatty acid deficiencies [36,38-41]. The
intake of dietary phospholipids such as PA and PS may
cause alterations and optimize the composition of cell
membranes which in turn may modulate cellular function
and activity of membrane [42].
The aim of the current study was to confirm the HPAA
normalizing effects of a dose of PAS 400 found in a previ-
ous study. Here, we were especially interested whether there
was a difference in effects between chronically stressed or
non-stressed people. Chronic stress was assessed by using
the screening scale for chronic stress of the Trier Inventory
for Chronic Stress (TICS) [43]. Cut-off for low versus high
chronic stress was defined as provided by a norm popula-
tion of the TICS authors. In addition, we wanted to investi-
gate whether these effects can also be observed with a
lower dosage of PAS 200. In order to investigate PAS effects
in a homogeneous study population, we included only male
subjects and enlarged group size. We investigated the ef-
fects of two different doses of PAS (200 mg PA & 200 mg
PS and 400 mg PA & 400 mg PS per day) over 42 days
compared to placebo on psychological and physiological
stress reactivity in subjects stratified by low and high
chronic stress levels.
Results
Baseline measures
Groups did not differ with respect to age, height, body
mass, BMI (body mass index), WHR (waist to hip ratio),
systolic blood pressure, diastolic blood pressure and heart
rate (Table 1). Furthermore, no baseline differences were
observed for measures of chronic stress (Trier Inventory
of Chronic Stress; TICS; all p > 0.05; data not shown) be-
tween all three treatment groups.
Compliance
Mean overall compliance was about 89.65% (SE = 1.30%)
as assessed by a medication event monitoring system
Table 1 Baseline measures
Age [years] Height [m] Body mass [kg] BMI [kg/m2] WHR Systolic blood
pressure [mmHG]
Diastolic blood
pressure [mmHG]
Heart rate [bpm]
Placebo group
Mean 26.64 1.81 83.68 25.45 0.86 127.64 71.08 69.16
SE 1.48 0.02 2.26 0.56 0.01 2.08 1.64 1.89
N 25 25 25 25 24 25 25 25
PAS 200 group
Mean 25.92 1.82 84.8 25.59 0.86 131.68 73.64 73.32
SE 1.32 0.02 3.11 0.73 0.01 1.5 2.11 2.49
N 25 25 25 25 25 25 25 25
PAS 400 group
Mean 26.48 1.83 85.2 25.59 0.87 129.12 73.56 71.2
SE 1.37 0.01 2.32 0.8 0.01 2.52 2.39 2.84
N 25 25 25 25 25 25 25 25
Group differencesa
χ2 0.077 0.250 0.684 0.252 0.550 2,717 1,011 1,758
df 2 2 2 2 2 2 2 2
p 0.962 0.882 0.711 0.882 0.760 0.257 0.603 0.415
abased on Kruskal Wallis H test.
PAS 200 group: 200 mg PA & 200 mg PS per day; PAS 400 group: 400 mg PA & 400 mg PS per day.
PA = phosphatidic acid, PS = phosphatidylserine, mg =milligrams, m =meter, kg = kilograms, mmHG =millimeter of mercury, bpm = beats per minute, SE = Standard
Error, N = Sample Size.
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counting of returned capsules. Analyses for covariance
were performed to explore the potential influence of
compliance on outcome measures. Neither MEMS® data
nor counting the returned capsules showed an effect of
compliance on ACTH, serum cortisol or saliva cortisol
response to the TSST (all p > 0.05, data not shown).
Stress responsivity
Acute stress was induced by the Trier Social Stress Test
(TSST). Induction of acute stress was confirmed by sig-
nificant time effects in repeated measures analyses of
variance for relevant variables. As expected, the TSST in-
duced a pronounced increase in salivary cortisol, serum
cortisol, and ACTH levels as well as heart rate and a de-
crease of pulse transit time (PTT) (see Table 2). The PTT
is determined by the R wave of the heart beat to the pulse
wave arrival at the finger. PTT is used as an index forTable 2 Biological stress response
Heart rate Pulse transit time
F 130.94 209.66
df, error df 1.98, 124.52 2.74, 147.89
p < 0.001 < 0.001
ηp
2 0.675 0.795
Significant p-values are written in bold letters.
ACTH = adrenocorticotropic hormone.arterial blood pressure [44-46] and as a biomarker for
stress reactivity. Acute stress is associated with an in-
creased blood pressure and a reduced PTT [47,48].
Furthermore, subjects showed an increase of state anxiety
(STAI: State-trait-anxiety inventory; VAS: visual analogue
scales), perceived stress, insecurity (VAS), and negative
mood (MDBF: Multidimensional mood state question-
naire) (Table 3).Treatment effects
We compared differences between treatment groups
(placebo, PAS 200 and PAS 400) and between subjects
scoring either high or low on a chronic stress inventory
(TICS). To compare general cortisol levels and cortisol
increases, we calculated the area under the curve with
respect to ground (AUCG) and its increase (AUCI) as de-
scribed by Pruessner and colleagues [49]. The AUCGSaliva Cortisol Serum Cortisol ACTH
116.270 116.27 199.22
2.10, 128.00 2.10, 128.0 1, 60
< 0.001 < 0.001 < 0.001
0.656 0.656 0.769
Table 3 Psychological stress response
MDBF STAI VAS
good mood alertness calmness state anxiety stress anxiety insecurity
F 42.04 28.22 74.43 64.13 49.96 34.46 67.95
df, error df 1, 65 1, 64 1, 64 1, 65 2, 128 1.81, 117.83 2, 130
p < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
ηp2 0.393 0.306 0.538 0.497 0.438 0.346 0.511
Significant p-values are written in bold letters.
STAI = state trait anxiety inventory, MDBF =multidimensional mood state questionnaire, VAS = visual analogue scale.
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the AUCI on cortisol increase and reactivity.Treatment group
Neither supplementation of PAS 200 nor of PAS 400 re-
sulted in significant effects on saliva or serum cortisol
levels on the overall study population (saliva cortisol:
AUCG: χ
2
2 = 0.44, p = 0.801; AUCI: χ
2
2 = 2.01, p = 0.366;
serum cortisol: AUCG: F2, 61 = 0.56, p = 0.576; AUCI: F2, 59 =
2.19, p = 0.121). For ACTH responses there was a
significant main effect of treatment group (F2, 59 = 3.66,
p = 0.032). Tukey post hoc tests revealed significant lower
ACTH levels in the PAS 400 group compared to the PAS
200 group (p = 0.025).Chronic stress level
Furthermore, no significant main effect of chronic stress
was observed for ACTH increases (F1, 59 = 1.820, p =
0.182), AUCG saliva cortisol (Z = −0.28, p = 0.783), and
AUCG serum cortisol (F1, 61 = 0.14, p = 0.721). However,
high chronically stressed subjects (HCS) showed a ten-
dency towards higher saliva cortisol AUCI (Z = −1.70,
p = 0.089) and significantly higher serum cortisol AUCILow chronic stress
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Figure 1 ACTH response to acute stress; *p < 0.05. PAS 200 group: 200 m
per day.(F1, 59 = 13.05, p = 0.001) than low chronically stressed
subjects (LCS).
Subgroup analysis
To further explore the impact of chronic stress levels on
treatment effects, we compared subgroups of HCS and
LCS.
HCS of the PAS 400 group showed significantly lower
increases of ACTH, serum cortisol, and saliva cortisol as
compared to the placebo and the PAS 200 group. These
effects could not be shown in LCS of the PAS 400 group.
Also, no differences were observed for HCS and LCS of
the PAS 200 group as compared to placebo. This sug-
gests that a supplementation with PAS 400 normalized
the enhanced ACTH- and cortisol-responses to an acute
stressor in subjects reporting a chronic stress load
(Figures 1, 2 and 3). The statistical information on ef-
fects of PAS on the endocrine stress response is pro-
vided in Table 4 for both HCS and LCS. Comparable to
our previous study [27], no effects of supplementation
were found for autonomic (heart rate; pulse transit time)
and for psychological response measures (mood, inse-
curity, perceived stress) in both low and high chronically
stressed subjects (data not shown). While we observedHigh chronic stress
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Figure 2 Serum cortisol response to acute stress; *p < 0.05. PAS 200 group: 200 mg PA & 200 mg PS per day; PAS 400 group: 400 mg PA &
400 mg PS per day.
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study, this effect was only marginal in the present study
(p < 0.07).
Discussion
In the present study, we investigated the effects of a 42-
day dose-dependent intake of PAS on biological and psy-
chological responses to the TSST in both HCS and LCS.
As expected, the TSST reliably induced robust biological
and psychological stress responses. Perceived stress re-
sponses were similar in all treatment groups. The pla-
cebo group showed a slight tendency for higher anxiety
(VAS) during the TSST as compared to the PAS groups.
Compliance assessed by MEMS® (about 90%) and by
counting remaining capsules (about 95%) was ratherSaliva Cortisol AUCG
LCS HCS
0
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800
Figure 3 Saliva cortisol response to acute stress; *p < 0.05. PAS 200 gro
400 mg PS per day.high. Differences between both might have been caused
by subjects taking their daily dose along to work with
only one opening of the track cap which then results in
a lower number of total openings. In that case the num-
ber of openings as assessed by MEMS® does not reflect
the number of intake occasions.
A pronounced stress dampening effect of PAS on
HPAA responses could only be observed for the 400 mg
treatment group in HCS. These data confirm our previ-
ous findings, and are in line with other studies showing
that acute and chronic administration of PS and PAS
can normalize cortisol responses to acute physical and
mental stress [27,30-32,34,35].
As addressed in the introduction, chronic stress can first
induce a hyper- and then a subsequent hypo-cortisolemicSaliva Cortisol AUCI
LCS HCS
0
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Placebo group
PAS 200 group 
PAS 400 group
*
up: 200 mg PA & 200 mg PS per day; PAS 400 group: 400 mg PA &
Table 4 Statistical information on group differences for AUCG and AUCI for salivary cortisol, serum cortisol and ACTH
levels in response to acute stress
low stressed subjects high stressed subjects
salivary cortisola
χ2 df p χ2 df p
AUCG 1.32 2 0.518 0.82 2 0.664
AUCI 0.43 2 0.805 6.48 2 0.039
Post hoc testing AUCI in high stressed subjects
b
Z p r
PAS 400 group vs. Placebo group −1.97 0.049 0.41
PAS 400 group vs. PAS 200 group −2.37 0.018 0.51
PAS 200 group vs. Placebo group −0.21 0.833
serum cortisolc
F df, error df p F df, error df p
AUCG 0.44 2, 31 0.651 0.55 2, 30 0.585
AUCI 0.09 2, 31 0.911 4.87 2, 28 0.015
Post hoc testing AUCI in high stressed subjects
d
p
PAS 400 group vs. Placebo group 0.035
PAS 400 group vs. PAS 200 group 0.033
PAS 200 group vs. Placebo group 0.995
ACTHe
F df, error df p F df, error df p
group difference 1.60 2, 30 0.218 2.43 2, 29 0.106
increase differences 0.31 2, 30 0.737 4.54 2, 29 0.019
Post hoc testing ACTH increase in high stressed subjectse
F df, error df p
PAS 400 group vs. Placebo group 8.22 1, 19 0.010
PAS 400 group vs. PAS 200 group 8.23 1, 20 0.009
PAS 200 group vs. Placebo group 0.25 1, 19 0.627
PAS 200 group: 200 mg PA & 200 mg PS per day; PAS 400 group: 400 mg PA & 400 mg PS per day.
Significant p-values are written in bold letters. Post hoc analyses are written in italic letters, ACTH = adrenocorticotropic hormone.
astatistics based on Kruskal Wallis H Test.
bstatistics based on Mann–Whitney U test.
cstatistics based on univariate analysis of variance.
dstatistics based on Tukey post hoc testing.
estatistics based on repeated measures analysis of variance.
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scribed in terms of a normalization of stress responsivity.
If chronic stress results in a hyper-responsivity of the
HPAA, as observed in this and other studies [15,27], phos-
pholipids can be expected to buffer the HPAA response to
stress. On the other hand, phospholipids may restore nor-
mal ACTH- and cortisol responses to stress in subjects
with a reduced HPAA response [13,28]. Notably, relax-
ation and stress management techniques show similar ef-
fects [50-55]. These observations support the assumption
that both phospholipids and relaxation can normalize the
HPAA-responsivity to stress.As in our previous PAS study, effects of PAS 400 could
only be observed for endocrine but not for autonomic
stress responses. If PAS would primarily affect the stress
response network in the brain, one would expect com-
mon secondary effects on psychological, endocrine, and
autonomic measures. This is unlikely, since in both stud-
ies psychological effects were inconsistent and auto-
nomic effects could not be observed. This points to the
possibility, that PAS primarily targets peripheral compo-
nents of the HPAA. Chronic stress has been shown to
reduce cortisol binding globulin (CBG) [56-58]. CBG is
a glycoprotein synthesized in the liver and secreted in
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acity to glucocorticoid hormones, such as cortisol in
humans and corticosterone in laboratory rodents. In
mammals, 95% of circulating glucocorticoids are bound
to either CBG (80%) or albumin (15%), and only the 5%
free fraction is able to enter the brain [59]. During stress,
the concentration of glucocorticoids rises significantly,
and the free fraction increases even more, once CBG be-
comes saturated. However, glucocorticoids unbound to
CBG are cleared from the blood more quickly. It is as-
sumed that CBG plays an important role in the fast ac-
tions of glucocorticoids on behavior by maintaining a
blood glucocorticoid pool that will be able to access the
brain for the fast effects of glucocorticoids [60,61].
The observed pronounced increase of ACTH and cor-
tisol in the TSST can possibly be explained by a drop of
CBG in chronically stressed subjects. If so, one may
hypothesize that PAS 400 first causes a normalization of
CBG levels under such conditions, which then would re-
sult in a normalization of the activity and reactivity of
the HPAA.
Conclusions
In chronically stressed subjects, PAS 400 can be expected
to buffer a hyper-responsivity of the HPAA to acute
stressors by normalizing cortisol responses. In contrast,
PAS 400 does not affect endocrine stress response in LCS
who do not have elevated cortisol levels. Although sample
sizes for subgroup analyses of chronic stress were rather
small, the results of this study are intriguing.
The CBG-hypothesis, derived from this study, can now
be tested to elucidate a possible relevant mechanism of
the action of PAS. If this hypothesis holds true, an indi-
cation of PAS for stress related disorders is evident, par-
ticularly for disorders which are considered to occur in
consequence of stress-elevated cortisol levels, such as
cardiovascular disease, central obesity, and the metabolic
syndrome [5,62]. In sum, we conclude that PAS 400
(MemreePlus™) is a safe and effective supplement for the
reduction of both physical and mental stress. Based on
the previous study, it can be speculated that women also
benefit from MemreePlus™ supplementation. This needs
to be confirmed in further studies.
Participants and methods
Participant selection
Healthy, non-smoking male volunteers between age 20
and 45 years were recruited by newspaper advertisement
and flyer distribution in the area of Trier, Germany. Sub-
jects’ health was assessed in a structured medical inter-
view by a study physician and by assessing clinical blood
chemistry. Individuals were not eligible if any of the fol-
lowing criteria applied: known allergies to ingredients of
the test substance, addiction to nicotine, drugs oralcohol, recent changes in nutritional habits (e.g. start of
a weight loss diet), any serious general illness within the
last 12 months, any febrile illness (longer than 24 hours)
within seven days prior to assessment, any intake of
antibiotics during the four weeks prior to study inclu-
sion, diabetes mellitus, heart disease, hypertension, kid-
ney disease, significant respiratory disease, or epilepsy,
immunologic or infectious disease (e.g. hepatitis, tuber-
culosis, HIV or AIDS, lupus, rheumatoid arthritis) which
could place the subject at risk or interfere with the ac-
curacy of the study results, current or past participation
in a TSST study, employee of the sponsor or CRO, medi-
cations that are likely to affect treatment response, or
any conditions that may affect the ability of the individ-
ual to complete the study or the interpretation of the
study results.
A total number of 124 subjects were screened for
study inclusion and exclusion criteria of which 75 male
subjects met the eligibility criteria. These subjects were
randomly assigned and stratified by chronic stress level
to one of the three treatment groups (25 subjects per
group: placebo, PAS 200, PAS 400). After study inclu-
sion, one subject of the placebo group and two subjects
of the PAS 200 group were lost to follow up, leaving 24
subjects of the placebo group, 23 subjects of the PAS
200 group, and 25 subjects of the PAS 400 group for
analysis (total sample size of 72 subjects) (see Figure 4).
The study protocol was approved by the ethical review
board of the Medical Association of Rhineland-Palatinate
(Mainz, Germany), and written informed consent was ob-
tained from all participants. The study was performed in
accordance with the ethical principles that have their origin
in the Declaration of Helsinki and are consistent with
International Conference on Harmonization/Good Clinical
Practice (2008).
Study design and procedures
This was a randomized, double-blind, placebo-controlled,
single-center study with three treatment arms (placebo,
PAS 200, PAS 400 daily for six weeks). The study included
four visits at the study site and had a total duration of
44 days for each subject.
Before subjects were invited to the study site, a first
screening took place by telephone interview. Here, sub-
jects received some general information on study proce-
dures as well as a first check of inclusion and exclusion
criteria. At visit one (V1), subjects received an extended
written information on the aim of this study and all de-
tailed study procedures. After clarifying possible ques-
tions, the signed written informed consent was obtained.
The study physician then assessed vital signs and took a
blood sample for determining safety parameters
(i.e. blood profile for hemoglobin, hematocrit, platelet
count, leukocytes, monocytes, neutrophils, eosinophils
Enrollment Assessed for eligibility (n= 124)
Excluded (n= 49)
-Not meeting inclusion criteria (n= 27)
-Declined to participate (n= 18)
-Other reasons (n= 4)aRandomized (n= 75)
Allocation
Placebo group
-Allocated to intervention (n= 25)
-Received allocated intervention
(n= 25)
PAS 200 group
-Allocated to intervention (n= 25)
-Received allocated intervention
(n= 25)
PAS 400 group
-Allocated to intervention (n= 25)
-Received allocated intervention
(n= 25)
Follow-Up
-Lost to follow-up (n= 0)
-Discontinued intervention (n= 2)
RID 025 did not keep appointment 
for V3, RID 055 did not keep 
appointment for V4
-Lost to follow-up (n= 0)
-Discontinued intervention (n= 0)
Analysis
-Analyzed (n= 24)
-Excluded from analysis (n= 1)
RID 041 dropped out because of 
physical condition
-Analyzed (n= 23)
-Excluded from analysis (n= 2)
RID 025 did not keep appointment 
for V3, RID 055 did not keep 
appointment for V4
-Analyzed (n= 25)
-Excluded from analysis (n= 0)
-Lost to follow-up (n= 1)
RID 041 dropped out because of
physical condition
-Discontinued intervention (n= 0)
Figure 4 Subject flow chart. PAS 200 group: 200 mg PA & 200 mg PS per day; PAS 400 group: 400 mg PA & 400 mg PS per day. aone subject spoke
only poor German, three subjects fulfilled the criteria for the high stressed subgroup when no additional subject was needed for this subgroup.
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Inventory for Chronic Stress (TICS [43]). Chronic stress
was determined using the Screening Scale for Chronic
Stress, a subscale of the TICS. For classification of low
and high chronic stress, the median value of 13 reported
by Schulz and colleagues [43] was used as a cut off
value. Thirty-five HCS and 35 LCS were randomly
assigned to one of the three treatment groups.
Randomization sequence was stratified with a 1:1 alloca-
tion using random blocks of variable sizes with the com-
puter software SPSS 20.0 (IBM Corporation, Somer NY;
USA).
At visit two (V2) those subjects meeting eligibility cri-
teria received a random number. According to the
randomization sequence, subjects received their daily
supplementation of 4 capsules for the following 21 days.
Capsules were packed in a container with a Medication
Event Monitoring System (MEMS®) track cap (Aardex
Ltd, Zug, Switzerland) to monitor container openingsand indicating protocol compliance. MEMS® recorded
time and date of each opening electronically. At visit
three (V3), MEMS® track caps were read out and sub-
jects received their supplementation dose for the follow-
ing three weeks. At the final study visit (V4), a post
supplementation blood sample for safety parameters
was taken and the Trier Social Stress Test (TSST); [63]
was performed to induce an acute psycho-social stressful
situation. At V2, V3 and V4 subjects were carefully checked
for adverse events and concomitant medication.
V4 had an overall duration of 180 minutes. Subjects
received their last supplement dosage 90 minutes prior
to the stress test. Pre- and post-stress psychometrics tests
were performed. For HPAA activity measures saliva (free
cortisol) and blood (total cortisol) samples were taken at
2 min. prior to the TSST as well as 1 min., 10 min.,
20 min., 30 min. and 60 min. after the TSST. Blood sam-
ples, taken at 2 min. prior and 1 min. after the TSST, were
also used for ACTH analyses.
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AG & Co., Nümbrecht, Germany). Blood samples were
collected using a vein catheter and 2.7 ml EDTA monov-
ettes® (Sarstedt AG & Co., Nümbrecht, Germany). Saliva
samples were stored at −20°C, blood samples were centri-
fuged and stored at −20°C and −80°C until all participants
completed the study.
Saliva cortisol levels were analyzed at the laboratory
of the University of Trier, Germany using a competitive
solid phase time-resolved fluorescence immunoassay
with flouromeric end point detection (DELFIA). The
intra- and interassay variability was below 10%.
ACTH was determined using a two-step immunoassay
with streptavidin microparticles and electrochemilumi-
nescence detection. Serum cortisol levels were analyzed
using an electrochemiluminescence immunoassay (ECLIA).
The assay is based on luminescence produced during
photochemical reactions in solutions. Both assays used
Elecsys® (Roche Diagnostics GmbH, Mannheim, Germany)
and their intra- and interassay variability was below 10%.
For measures of the autonomic nervous system, heart
rate and pulse transit time (PTT) were measured con-
tinuously from 20 min. prior to the TSST to 20 min.
after the TSST using an electrocardiogram device (SOM-
NOscreen™ plus, SOMNOmedics GmbH, Randersacker,
Germany). PTT is determined by measuring the electro-
cardiography and the pulse wave at a finger. Studies in-
dicate that PTT is an appropriate parameter for stress
measurement [48,64].
Psychometric assessment included a mood question-
naire MDBF [65], before and after the TSST. State anxiety
was assessed with the STAI-X1 [66] before and after the
TSST. Furthermore, levels of perceived anxiety, stress and
insecurity were measured before, during and after the
TSST, as described by Hellhammer and Schubert [67].
Study treatment
The study supplement PAS (produced by Lipogen
Ltd, Israel) and sold as “MemreePlus™” by Lonza Ltd,
Switzerland was administered in capsules. Lipogen holds a
patent (US 6,410,522 & EP 1201244) and the supplement
has an US FDA GRAS (Generally Recognized As Safe) sta-
tus. In this study, 4 capsules were administered per day:
subjects were asked to take two capsules in the morning,
one at noon and one in the evening with a glass of water
after meals. Single capsules of the PAS 400 group (400 mg
PA & 400 mg PS per day) consisted of 100 mg phosphati-
dylserine (PS) and lysophosphatidylserine, 100 mg phos-
phatidic acid (PA) and lysophosphatidic acid, 235 mg other
phospholipids and glycerides, 5 mg silicone dioxide. Single
capsules of the PAS 200 group (200 mg PA & 200 mg PS
per day) consisted of 50 mg phosphatidylserine (PS) and
lysophosphatidylserine, 50 mg phosphatidic acid (PA) and
lysophosphatidic acid, 335 mg other phospholipids andglycerides, 5 mg silicone dioxide. Placebo capsules con-
tained 435 maize starch and 5 mg silicone dioxide. All cap-
sules were identical in size, shape and colour.Stress test
The Trier Social Stress Test TSST; [63] was established
in 1993 combining key elements of social stress with
novelty, unpredictability, uncontrollability and ego-
involvement in a standardized laboratory protocol for
approximately15 minutes. Since then, it has been used
in many clinical studies and in various areas of research.
A meta-analysis of stress test protocols of Dickerson
and Kemeny [68] showed that the protocol of the TSST
is most effective in provoking HPAA responses. Further-
more, the TSST has been shown to provoke a strong in-
crease in an individual’s perception of stress, insecurity
and anxiety [67].
The TSST protocol compromises an introduction by
the study manager: the subject is introduced to a panel
and is asked to prepare for a job interview in a new
company. After this introduction, the study manager
leaves the TSST-room and the subject had a 3-min.
period to prepare for the job interview. The 5-min. inter-
view is followed by a 5 min. mental arithmetic task, step-
wise subtracting 17 from 2023 as quickly and correctly
as possible. The TSST is terminated by the study man-
ager leading the participant back to every participant’s
individual room. All TSSTs were conducted in the after-
noon to control for diurnal cycles.Statistical analysis
For statistical analyses, we used the software SPSS 21
(IBM Corporation, Somer NY, USA). For statistical infer-
ence, different statistical tests were performed. Only two-
sided tests were used and data were interpreted on an
α-level below 5% (α < .05). Baseline characteristics and
demographics as well as data violating normality distri-
bution were analyzed using Kruskal Wallis H test.
For cortisol the area under the curve with respect to
ground (AUCG) and its increase (AUCI) were calculated
using the formula described by Pruessner and colleagues
[49]. The AUCG holds information about general cortisol
levels, as it is an integrated value of all measurements.
The AUCI holds information about the increase of corti-
sol levels, as it is an integrated value of all measurements
adjusted for the cortisol level under resting conditions.
For salivary cortisol AUCG and AUCI we conducted
Kruskal-Wallis-H-tests for effects of treatment groups
and Mann–Whitney-U-tests for treatment group to treat-
ment group comparison and for effects of chronic stress
level. For serum cortisol AUCG and AUCI we conducted
univariate analyses of variance with treatment group and
chronic stress level as fixed factors. Post hoc comparison
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http://www.lipidworld.com/content/13/1/121was done with Tukey post hoc testing. For ACTH we con-
ducted repeated measures analyses of variance with treat-
ment group and chronic stress level as factors. Post hoc
comparison of treatment groups was done with Tukey
post hoc testing. Post hoc comparison of increase differ-
ences was done by repeated measures analyses of variance,
with analysis-filters for relevant groups.
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